UNSPSC 51263126: Metipranolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C17H27NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X39AL81KEB, chemically known as 4-(2-hydroxy-3-((1-methylethyl)-amino)propoxy)-2,3,6-trimethylphenol 1-acetate but generally known as metipranolol, which bears US NIH Compound Identifier 31477. European Medicines Agency schedules Metipranolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08892MIG.

UNSPSC 51263126 Metipranolol is a Commodity code that nominally covers a specific beta-blocker pharmaceutical, but recent state and local procurement activity under this code shows minimal relevant solicitation. The only recent opportunity on record—Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems—addresses opioid-reversal agents and harm-reduction equipment rather than metipranolol or the glaucoma and cardiovascular applications the commodity code suggests. The mismatch between the code's scope and actual buying behavior indicates either a miscoding issue in the procurement system or extremely limited activity aligned with the metipranolol commodity itself.

No recent state and local opportunities directly soliciting metipranolol or closely related ophthalmic and cardiovascular beta-blockers appear in the record. Procurement professionals evaluating this code should verify whether issuing bodies are tagging metipranolol purchases under a different UNSPSC code, whether demand exists at all in the state and local market, or whether the single Naloxone record represents a systemic classification error. Until evidence of actual metipranolol buying emerges across multiple jurisdictions, this code does not signal actionable procurement opportunity.